Last reviewed · How we verify
Clenil® Modulite® via Volumatic™ spacer — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Clenil® Modulite® via Volumatic™ spacer (Clenil® Modulite® via Volumatic™ spacer) — Chiesi Farmaceutici S.p.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clenil® Modulite® via Volumatic™ spacer TARGET | Clenil® Modulite® via Volumatic™ spacer | Chiesi Farmaceutici S.p.A. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clenil® Modulite® via Volumatic™ spacer CI watch — RSS
- Clenil® Modulite® via Volumatic™ spacer CI watch — Atom
- Clenil® Modulite® via Volumatic™ spacer CI watch — JSON
- Clenil® Modulite® via Volumatic™ spacer alone — RSS
Cite this brief
Drug Landscape (2026). Clenil® Modulite® via Volumatic™ spacer — Competitive Intelligence Brief. https://druglandscape.com/ci/clenil-modulite-via-volumatic-spacer. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab